TWi Pharmaceuticals

1 2

/ Press Releases: 2017.06; TWi Confirms Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Tecfidera; 2017.04; TWi Signed a Cooperation Agreement with Intech for US Inhalation Market; 2017.02; TWi Confirms Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Axiron; 2017.01; TWi Settles Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Restasis; 2016.12; TWi Bio is officially listed on Emerging Market of Taipei Exchange